plc Developing Innovative Peptides April 2020
ImmuPharma • Listed on AIM (LSE:IMM) & Euronext Growth Brussels (ALIMM) • Pipeline of innovative peptide products • Portfolio from early to late stage • Lupuzor ™ - lead product for Lupus - gearing up to start optimised Phase III international trial • US partner ‘ Avion ’ signed in Q4 2019 - funding Lupus trial • Discovery labs in France 2
Recent update £1.5 million Subscription • Issue of 15,000,000 new ordinary shares of 10P each comprising: o £200k from Dr Robert Zimmer (President & CSO of IMM) o £1.3m with Lanstead Capital (major shareholder) • Proceeds will be used primarily to fund: o Expansion of the Company’s R&D programmes; and o General working capital Expansion of R&D programmes - 4 therapy areas • Autoimmunity; Anti-Infectives; Metabolism & Cancer Highlights • Strengthened advisory team for Lupuzor ™ intl. Phase III trial • Proof of Concept study planned for Lupuzor ™ in CIDP patients • New BioGlucagon product - potential market launch in 2022 • 3 new Anti-Infective programmes including BioAMP-B 3
£1.3m Lanstead Subscription 13m shares placed with Lanstead at 10p per share = £1.3m IMM receives the proceeds back over 24 months starting in July 2020 Amount received on monthly basis dependent on 20-day volume weighted average share price (VWAP) each month If VWAP exceeds 13.33p Benchmark Price, IMM gets proportionately more, if lower, proportionately less Agreement reflects confidence of management and Lanstead in the future of IMM Further supportive investment with Lanstead following: £4.43m investment and sharing agreement in February 2016, where IMM received >£5.0m £2.66m investment in June 2019 which was invested in ongoing sharing agreement with Lanstead, currently ahead on cumulative settlements to date 4
Key programmes Autoimmunity Metabolism BioGlucagon Lupuzor ™ for Lupus & CIDP Innovative Peptides Anti- infective BioAmp-B 5
Lupuzor ™ • Lupuzor ™ ( forigerimod) is more than just Lupus • Many more indications • Multifunctional • Underlying mechanism of action of Lupus occurs in other diseases 6
Lupuzor ™ for Lupus Lupus • Autoimmune chronic inflammatory disease • Unmet market need - lack of safe and effective treatments • Multi-billion sales potential • Patients*: >5m globally | 1.5m lupus sufferers in EU/US/Japan • GSK’s approval of Benlysta in 2011 paves the path to market Lupuzor ™ • Novel mechanism that modulates (not blocks) immune system • Outstanding safety profile Attractive economics • Lupus patients treated by specialists = low marketing costs • Benlysta priced at approx. US$40,000 / per patient / per year • Lupuzor ™ anticipated to have competitive pricing with higher margins * source: Lupus Foundation of America ‘www.lupus.org’ ( 2019) 7
Lupuzor ™ fully funded for lupus – US deal with Avion • New ‘optimized’ international Phase III trial • Exclusive rights for US with Avion • Lupuzor ™ Phase III funded up to $25m • Milestones up to $70m & tiered double-digit HQ: Georgia USA with >200 employees Fully integrated in drug development, sales royalties up to 17% and marketing • Focus on Rheumatology, Neurology, Endocrine Data from Phase III trial allows approvals in and Women’s Health key ex-US markets Annual sales >$250m, strong growth (50% pa) Strong balance sheet, well funded • Discussions continue with potential partners Focus on low competition / high margin branded opportunities for Lupuzor ™ outside of US Sustained pipeline of new opportunities 8
Avion’s strengthened advisory team • Collaboration with leading Lupus patient group & formation of Board of KOLs • Key decisions/next steps agreed prior to FDA meeting to include: • Structure of optimised intl. Phase III Lupuzor ™ trial • Demographics and patient inclusion criteria • Guidance on key territories where trial to be conducted As part of the Phase III trial, these advisors will provide: • Support and expedition to identify / recruit Lupus patients for trial • Promotion to patient steering groups to raise awareness of Lupuzor ™ to Lupus patients and clinicians throughout trial 9
Lupuzor ™ for CIDP • CIDP * is a neurological disorder targeting the body’s nerves • Symptoms: fatigue and weakness, numbness, tingling in limbs • Unique MOA ** of Lupuzor ™ *** demonstrates effectiveness in auto- immune diseases including ‘CIDP’ • CIDP could be granted ‘Orphan Drug Designation’ due to the unmet clinical need with ~50-100k patients in the US/EU • Fast approval process could apply • Sales potential > $500m annually • Currently no effective approved drug on the market • Next steps : • ‘Proof of Concept’ study in CIDP patients based on the strong data already gained within IMM’s Lupus dossier • Partnering opportunities *Chronic Inflammatory Demyelinating Polyneuropathy ** Mechanism of Action ***Also known as Forigerimod or P140 10
Metabolism – ‘New’ BioGlucagon • BioGlucagon is a potential new rescue therapy for low sugar events in diabetes • Existing glucagon products; poor solubility, inconvenient - variable dosing creates risks for patients • BioGlucagon has 100% solubility, can be formulated in pre-filled syringe pens and could be used in insulin pumps • Sales of existing products approx. $500m (p.a.) • Next steps: • Bio equivalence study, with potential market launch date in 2022 • Partnering opportunities 11
Anti-Infectives – ‘New’ BioAMP-B Anti-fungal opportunity • BioAMP-B is a novel peptide-based drug that offers a potential improvement on Amphotericin- B (“Amp - B”) • Amp-B one of the few effective treatments for serious and life threatening fungal infections such as aspergillosis (lung infection) • Leading AMP- B, ‘ Ambisome ’ causes serious kidney toxicity in c.15% of patients • BioAMP- B’s target profile has superior safety profile to Ambisome • Sales of Ambisome in 2019 were $407m (p.a.) • Next steps: • Bio equivalence study, with potential market launch date in 2022 • Partnering opportunities *The World Health Organisation 12 ** (National Academy of Medicine: 2016 )
Not just a Lupus story - value enhancing news flow & milestones 2020 2021 2022 Avion Phase III Lupuzor ™ Avion Phase III Lupuzor ™ Avion Phase III Lupuzor ™ progress updates progress updates progress updates Autoimmunity CIDP ‘POC’ preparation CIDP ‘POC’ study Lupuzor ™ ex US partnering opportunities BioGlucagon preparation for BioGlucagon bioequivalence BioGlucagon filing, bioequivalence study target launch study Metabolism BioGlucagon partnering opportunities Bio-AMP-B preparation Bio-AMP-B bioequivalence Bio-AMP-B filing, for bioequivalence study target launch study Anti-Infectives Bio-AMP-B partnering opportunities 2020 2021 2022 13
Investment summary • Latest investment from Lanstead Strong endorsement of IMM’s technology platform • • Lupuzor ™ fully funded by US partner Avion Moving into optimised Phase III intl. trial • • Near term inflexion points Continued strong news flow • • Partnering opportunities Lupuzor ™ in key territories outside of US • Lupuzor ™ for CIDP • BioGlucagon & BioAmP-B • 14
15
Recommend
More recommend
